Chronic graft-versus-host disease: Current situation and unmet needs - A European position statement - PubMed
4 days ago
- #hematopoietic cell transplantation
- #cGVHD
- #immune dysregulation
- Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and non-relapse mortality post allogeneic hematopoietic cell transplantation.
- The disease involves immune dysregulation, aberrant tissue repair, and fibrosis, leading to a varied clinical spectrum that severely affects quality of life.
- Recent therapeutic advances include JAK inhibition, ROCK2 inhibition, and CSF-1R-directed therapies, offering alternatives to corticosteroids.
- Challenges remain in diagnosis, staging reproducibility, and integrating patient-reported outcomes into clinical trials.
- There is a significant pharmaco-economic burden associated with cGVHD, highlighting the need for more effective and accessible treatments.
- The review proposes a collaborative approach focusing on precision medicine, harmonized assessment tools, and international research networks to improve outcomes.